X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ASTRAZENECA PHARMA with Aventis Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs SANOFI INDIA - Comparison Results

ASTRAZENECA PHARMA    Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

SANOFI INDIA 
   Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA SANOFI INDIA ASTRAZENECA PHARMA/
SANOFI INDIA
 
P/E (TTM) x 119.0 32.8 362.9% View Chart
P/BV x 16.9 6.2 271.4% View Chart
Dividend Yield % 0.0 1.4 -  

Financials

 ASTRAZENECA PHARMA   SANOFI INDIA
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-14
SANOFI INDIA
Dec-16
ASTRAZENECA PHARMA/
SANOFI INDIA
5-Yr Chart
Click to enlarge
High Rs1,2854,560 28.2%   
Low Rs6344,400 14.4%   
Sales per share (Unadj.) Rs189.61,028.5 18.4%  
Earnings per share (Unadj.) Rs-0.2129.0 -0.2%  
Cash flow per share (Unadj.) Rs3.8186.0 2.1%  
Dividends per share (Unadj.) Rs068.00 0.0%  
Dividend yield (eoy) %01.5 0.0%  
Book value per share (Unadj.) Rs68.6753.6 9.1%  
Shares outstanding (eoy) m25.0023.03 108.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.14.4 116.2%   
Avg P/E ratio x-4,712.734.7 -13,566.0%  
P/CF ratio (eoy) x249.624.1 1,036.1%  
Price / Book Value ratio x14.05.9 235.2%  
Dividend payout %052.7 0.0%   
Avg Mkt Cap Rs m23,988103,174 23.2%   
No. of employees `0001.63.6 43.0%   
Total wages/salary Rs m1,6053,592 44.7%   
Avg. sales/employee Rs Th3,040.26,537.7 46.5%   
Avg. wages/employee Rs Th1,029.2991.4 103.8%   
Avg. net profit/employee Rs Th-3.3819.8 -0.4%   
INCOME DATA
Net Sales Rs m4,74023,686 20.0%  
Other income Rs m92708 13.0%   
Total revenues Rs m4,83224,394 19.8%   
Gross profit Rs m-1305,281 -2.5%  
Depreciation Rs m1011,313 7.7%   
Interest Rs m015 0.0%   
Profit before tax Rs m-1394,661 -3.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1390-   
Tax Rs m51,691 0.3%   
Profit after tax Rs m-52,970 -0.2%  
Gross profit margin %-2.722.3 -12.3%  
Effective tax rate %-3.736.3 -10.1%   
Net profit margin %-0.112.5 -0.9%  
BALANCE SHEET DATA
Current assets Rs m2,72615,673 17.4%   
Current liabilities Rs m2,4356,678 36.5%   
Net working cap to sales %6.138.0 16.2%  
Current ratio x1.12.3 47.7%  
Inventory Days Days7476 97.0%  
Debtors Days Days4122 182.7%  
Net fixed assets Rs m1,0358,098 12.8%   
Share capital Rs m50230 21.7%   
"Free" reserves Rs m94217,088 5.5%   
Net worth Rs m1,71617,356 9.9%   
Long term debt Rs m00-   
Total assets Rs m4,15625,400 16.4%  
Interest coverage xNM311.7-  
Debt to equity ratio x00-  
Sales to assets ratio x1.10.9 122.3%   
Return on assets %-0.111.8 -1.0%  
Return on equity %-0.317.1 -1.7%  
Return on capital %026.9 0.0%  
Exports to sales %5.724.5 23.3%   
Imports to sales %6.528.0 23.1%   
Exports (fob) Rs m2705,801 4.7%   
Imports (cif) Rs m3066,627 4.6%   
Fx inflow Rs m3757,145 5.2%   
Fx outflow Rs m4706,846 6.9%   
Net fx Rs m-96299 -32.0%   
CASH FLOW
From Operations Rs m-83,226 -0.3%  
From Investments Rs m-146-1,555 9.4%  
From Financial Activity Rs m862-1,818 -47.4%  
Net Cashflow Rs m709-147 -482.0%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 75.0 60.4 124.2%  
Indian inst/Mut Fund % 0.3 14.4 2.1%  
FIIs % 15.7 14.6 107.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 10.5 86.7%  
Shareholders   12,856 15,184 84.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   GSK PHARMA  JUBILANT LIFE SCIENCES  BIOCON LTD  IPCA LABS  ALKEM LABORATORIES  

Compare ASTRAZENECA PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Strong; Infosys & Axis Bank Top Gainers(01:30 pm)

After opening the day in green, the Indian share markets have continued the momentum and are presently trading on a strong note.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Is it Wise to Ignore Bitcoins?(The 5 Minute Wrapup)

Jan 4, 2018

While investing in bitcoins, it would make sense to treat it as another asset class and decide accordingly.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Jan 17, 2018 02:53 PM

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 8-QTR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS